glycyl=>glycyl=>asparagine ; [N-(N-glycyl-glycyl)-L-aspartic acid ]-4-amide | 70019-75-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: glycyl=>glycyl=>asparagine ; [N-(N-glycyl-glycyl)-L-aspartic acid ]-4-amide
• 英文别名: L-2-[(Aminoacetyl-amino)-acetamino]-bernsteinsaeure-4-amid；[N-(N-Glycyl-glycyl)-L-asparaginsaeure]-4-amid；Glycyl=>glycyl=>asparagin; [N-(N-Glycyl-glycyl)-L-asparaginsaeure]-4-amid；Gly-Gly-Asn；(2S)-4-amino-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-4-oxobutanoic acid
• CAS: 70019-75-9
• 化学式: C₈H₁₄N₄O₅
• 分子量: 246.223
• InChiKey: KMSGYZQRXPUKGI-BYPYZUCNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -5.8
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  165
• 氢给体数：
  5
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  NΑ-甘氨酰-L-天冬酰胺酸 在 sodium hydroxide 、 氨 、 水 作用下， 生成 glycyl=>glycyl=>asparagine ; [N-(N-glycyl-glycyl)-L-aspartic acid ]-4-amide
  参考文献：
  名称：

  Suzuki, Journal of Biochemistry, 1931, vol. 13, p. 57,70

  摘要：

  DOI：

文献信息

• Method For Preparing Hexahydrofuro-Furanol Derivative, Intermediate Thereof And Preparation Method Thereof
  申请人：Jiangsu Ruike Medical Science And Technology Co., Ltd.

  公开号：US20210009544A1

  公开（公告）日：2021-01-14

  The invention relates to the field of pharmaceutical synthesis, in particular to a preparation method of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol derivatives and their intermediates. The preparation method is carried out starting from compound Formula A1. In the preparation of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol derivatives, the chirality was constructed by enzymatic method, and the products were prepared with high optical purity. The preparation method can be used to produce the key intermediates of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol of darunavir commercially, which is a very economical route suitable for industrial production.

  本发明涉及制药合成领域，特别是一种(3R,3aS,6aR)-六氢呋喃[2,3-b]呋喃-3-醇衍生物及其中间体的制备方法。该制备方法从化合物A1开始进行。在制备(3R,3aS,6aR)-六氢呋喃[2,3-b]呋喃-3-醇衍生物时，手性通过酶法构建，产品具有高光学纯度。该制备方法可用于商业生产达芦那韦的(3R,3aS,6aR)-六氢呋喃[2,3-b]呋喃-3-醇的关键中间体，是一种非常经济的途径，适合于工业生产。
• Radiolabeled technetium chelates for use in renal function determinations
  申请人：UNIVERSITY OF UTAH RESEARCH FOUNDATION

  公开号：EP0173424A1

  公开（公告）日：1986-03-05

  The present invention is directed to novel radiopharmaceutical imaging agents incorporating Tc-99m as a radiolabel. In particular, the novel imaging agents disclosed herein have relatively high renal extraction efficiencies, and hence are useful for conducting renal function imaging procedures. The novel Tc-99m compounds of a present invention have the following general formula: wherein X is S or N; and wherein Y is -H2 or wherein Y is and where R, is -H, -CH3, or -CH2CH3; R2 is -H, -CH2CO2H, -CH2CONH2, -CH2CH2C02H, -CH2CH2CONH2, -CH3, -CH2CH3, CH2C6H5, or -CH20H; and Z is -H, -CO2H, -CONH2, -S03H, -SO2NH2, or -CONHCH2C02H; and the Tc is Tc-99m; and water-soluble salts thereof. Of the foregoing, the presently preferred Tc-99m compound of the present invention is Tc-99m-mercaptoacetylglycylglycylglycine (Tc-99m-MAGGG). The present invention is also directed to novel chelating agents that may be reacted with Tc-99m to form the foregoing compounds. Such novel chelating agents have the following general formula. where X and Y have the same definitions as above, and wherein Y' is -H2 when X is N, or wherein Y' is -H, or a suitable protective group such as -COCH3, -COC6H5, -CH2NHCOCH3, -COCF3, or -COCH20H when X is S. The present invention also provides methods for preparing and using the novel Tc-99m compounds.

  本发明涉及以 Tc-99m 为放射性标记的新型放射性药物成像剂。特别是，本发明公开的新型成像剂具有相对较高的肾提取效率，因此可用于进行肾功能成像程序。本发明的新型 Tc-99m 化合物具有以下通式： 其中 X 是 S 或 N；Y 是 -H2 或 Y 是 其中 R 是-H、-CH3 或-CH2CH3；R2 是-H、-CH2CO2H、-CH2CONH2、-CH2CH2C02H、-CH2CH2CONH2、-CH3、-CH2CH3、CH2C6H5 或-CH20H；Z是-H、-CO2H、-CONH2、-S03H、-SO2NH2或-CONHCH2C02H；Tc是Tc-99m；以及它们的水溶性盐。在上述化合物中，本发明目前优选的 Tc-99m 化合物是 Tc-99m-巯基乙酰甘氨酰甘氨酸（Tc-99m-MAGGG）。本发明还涉及可与 Tc-99m 反应生成上述化合物的新型螯合剂。此类新型螯合剂具有以下通式。 其中 X 和 Y 的定义同上，当 X 为 N 时，Y'为-H2；当 X 为 S 时，Y'为-H 或合适的保护基团，如-COCH3、-COC6H5、-CH2NHCOCH3、-COCF3 或-COCH20H。 本发明还提供了制备和使用新型 Tc-99m 化合物的方法。
• Recombinant Alzheimer's amyloid protein
  申请人：CALIFORNIA BIOTECHNOLOGY, INC.

  公开号：EP0274826A1

  公开（公告）日：1988-07-20

  DNA sequences encoding the β-amyloid core protein, and β-amyloid-related proteins associated with Alzheimer's disease are disclosed. These sequences are used in producing or constructing recombinant β-amyloid core protein, β-amyloid-related proteins and recombinant or synthetic immunogenic peptides. These sequences are also used to identify genomic mutations and/or restriction site alterations which are associated with a predisposition to Alzheimer's disease, for purposes of genetic screening. Antibodies generated against the recombinant proteins or immunogenic peptides derived therefrom can be used for cerebral fluid or serum protein diagnosis of Alzheimer's disease.

  本研究公开了编码与阿尔茨海默病相关的β淀粉样核心蛋白和β淀粉样相关蛋白的DNA序列。这些序列可用于生产或构建重组β-淀粉样核心蛋白、β-淀粉样相关蛋白和重组或合成免疫原肽。这些序列还可用于鉴定与阿尔茨海默病易感性相关的基因组突变和/或限制位点改变，以进行基因筛选。针对重组蛋白或由其衍生的免疫原肽产生的抗体可用于阿尔茨海默病的脑液或血清蛋白诊断。
• A fibronectin binding protein as well as its preparation
  申请人：ALFA-LAVAL AGRI INTERNATIONAL AB

  公开号：EP0294349A2

  公开（公告）日：1988-12-07

  The present invention relates to a new recombinant hybrid-DNA­-molecule comprising a nucleotide sequence from S. aureus cod­ing for a protein, or polypeptide, having fibronectin binding properties.

  本发明涉及一种新的重组杂交 DNA 分子，该分子包含来自金黄色葡萄球菌的核苷酸序列，该核苷酸序列编码一种具有纤连蛋白结合特性的蛋白质或多肽。
• Anti-feline calicivirus recombinant antibody and gene fragment encoding the same
  申请人：Juridical Foundation The Chemo-Sero-Therapeutic Research Institute

  公开号：EP0561194A2

  公开（公告）日：1993-09-22

  Anti-FCV (feline calicivirus) feline-type recombinant antibody effective for treatment, prevention and diagnosis of FCV infection and a gene fragment useful for preparation of said antibody are provided. Cell line lD7 capable of producing a mouse monoclonal antibody having an excellent FCV-neutralizing activity was constructed and a gene fragment coding for the V region in charge of the FCV-specific binding of said antibody was obtained. This gene fragment and the gene coding for the constant region of the feline antibody are used to give a chimeric anti-FCV recombinant antibody. The obtained recombinant antibody is a novel antibody and is useful for the diagnosis, treatment and prevention of feline virus infections, particularly feline calicivirus infection, with high safety in administration into cats.

  本发明提供了有效治疗、预防和诊断 FCV 感染的抗 FCV（猫嗜热病毒）猫型重组抗体以及用于制备所述抗体的基因片段。本研究构建了能够产生具有极佳 FCV 中和活性的小鼠单克隆抗体的细胞系 lD7，并获得了负责该抗体 FCV 特异性结合的 V 区编码基因片段。利用该基因片段和猫科动物抗体恒定区的编码基因，可以得到嵌合的抗 FCV 重组抗体。获得的重组抗体是一种新型抗体，可用于诊断、治疗和预防猫科动物病毒感染，尤其是猫科动物卡里科病毒感染，给猫用药安全性高。